SPOTLIGHT -
Fidaxomicin Superior to Vancomycin in Reaching Desired C Difficile Outcomes
Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.
Recurrent CDI Hospitalization in Patients with IBD May Not Increase Adverse Event Risk
Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.
Engraftment of SER-109 Durable, Linked to Sustained Reduction in CDI Recurrence
SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.
RBX2660 Showed Consistent Success Compared to Placebo in CDI Treatment
Most adverse events reported were mild or moderate and found in a similar percentage of patients regardless of treatment cohort.
Millie D. Long, MD: Expanding the Safety Data on Ustekinumab
New data suggests there is no connection between ustekinumab and the risk of malignancies.
Paul Feuerstadt, MD: The Future of C Difficile Treatment
There are several companies preparing new treatments for recurrent C difficile infections.
Kanika Sehgal, MBBS: The State of C Difficile Care
There are several potential treatments on the horizon for C difficile infections.
Bruce Sands, MD: Efficacy of Mirikizumab for UC Treatment in LUCENT-1 Trial
At DDW 2022, Dr. Sands highlights the positive findings from the LUCENT-1 study on the efficacy and safety of mirikizumab.
Millie Long, MD: The Safety of Ustekinumab
Patients treated with ustekinumab are not at an increased risk of malignancies.
Kanika Sehgal, MBBS: The Psychological Distress of C Difficile Patients
Treating the disease could reduce the risk of patient distress.
Paul Feuerstadt, MD: New Data on RBX2660 at DDW 2022
There are several live microbiota therapeutics in development, including RBX2660.
Bruce Sands, MD: Safety of Ustekinumab Among Bionaive Patients with IBD
Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.
Jean-Frederic Colombel, MD: Promising Data on Upadacitinib for Crohn's Disease
The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.
Amit Singal, MD: Role of Biomarkers in HCC Risk Stratification, Screening
A discussion on the role of PLSec-AFP for HCC risk stratification in patients with cirrhosis and future screening implementations.
Safety Profile of Ustekinumab Favorable in Patients with IBD, History of BIologic Failure
Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.
Aasma Shaukat, MD, MPH: Better Detection on Colonoscopies
The age of screening for colon cancer has decreased in recent years.
Marla C. Dubinsky, MD: The Next Revolution for IBD Treatments
Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.
Yen-I Chen, MD: EUS-CDL Comparable to ERCP-M in ELEMENT Trial
The findings show EUS-CDL is more efficient than ERCP-M with comparable short-term effectiveness and safety.
Multiple Risk Factors Increase Risk for VTE After Surgery for IBD
Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively
Dupilumab Continues to Show Benefit in Treating EoE
The treatment recently became the first ever FDA-approved medication for EoE.
CP101 Prevented Recurrence of C Difficile Infection in PRISM-EXT Trial
Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.
Raseen Tariq, MBBS: FMT for Refractory Host Versus Graft Disease
Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.
Lack of Association Observed Between BMI and Mortality Among C Difficile Hospitalizations
BMI did not have an association with increased risk for death in any BMI category, according to study investigators.
Miguel Regueiro, MD: Safety Data on Ozanimod for Ulcerative Colitis
A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.
SER-109 Results in Increase in Microbe-Producing Metabolites
The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.
Taha Qazi, MD: Male Sexual Dysfunction Following Ulcerative Colitis Surgery
Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.
TNF-Antagonist Therapy Linked to Better Outcomes for Post-Operative Crohn’s Disease
Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.
DDW Research Shows No Efficacy for Vedolizumab in Treating NAFLD
Patients with IBD are often at an increased risk of developing NAFLD.
Bariatric Surgery Linked to Improved Outcomes After Myocardial Infarction
New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.
Ken Blount, PhD: Effect of RBX2660 on Microbiome and Bile Acid Composition
Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.
